PCSK9 and cardiovascular disorder: Numerous epidemiologic and genetic evidence supports the causal role of Lp(a) in the development of cardiovascular diseases (CVD) [3, 4] Despite the absence of specific Lp(a)-lowering therapies, sub-analyses of randomized trials on the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors suggested the potential benefit of reducing Lp(a) in event reduction secondary to lowering low-density lipoprotein cholesterol (LDL-C) [5, 6].